Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 13Uterine Cervical Dysplasia 5Papillomavirus Infections 5Neoplasms 2Atypical Squamous Cells of the Cervix 2Uterine Neoplasms 1Uterine Diseases 1Uterine Cervical Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Squamous Intraepithelial Lesions 1Precancerous Conditions 1Papilloma 1Neoplasms, Squamous Cell 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Genital Neoplasms, Female 1Genital Diseases, Female 1Genital Diseases 1Female Urogenital Diseases and Pregnancy Complications 1Anus Neoplasms 1

Interventions

anlotinib 2Ocoxin 2Bevacizumab 2pembrolizumab 1olaparib 1niraparib 1lenvatinib 1catumaxomab 1Papanicolaou Test 1Paclitaxel 1Human Papillomavirus DNA Tests 1Filgrastim 1Drug Therapy 1Colposcopy 1Cell Count 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × Human Papillomavirus DNA Tests × Gynecologic × Clear all
NCT01234480 2023-05-16

Intended Use Study of the BD SurePath Plusâ„¢ Pap

Becton, Dickinson and Company

Terminated
5,859 enrolled 4 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡